

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



愛 帝 宮 母 嬰 健 康 股 份 有 限 公 司
AIDIGONG MATERNAL & CHILD HEALTH LIMITED

(Incorporated in Bermuda with limited liability)

(Stock code: 286)

**RESIGNATION OF DIRECTOR;
CHANGES IN COMPOSITION OF BOARD COMMITTEES;
DIVERSITY OF BOARD MEMBERS UNDER RULE 13.92 OF
THE LISTING RULES
AND
CLARIFICATION ANNOUNCEMENT**

RESIGNATION OF DIRECTOR

The board (the “**Board**”) of directors (the “**Directors**”) of Aidigong Maternal & Child Health Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) announces that Ms. Meng Lijia (“**Ms. Meng**”) resigned as executive Director, a member of each of remuneration committee (the “**Remuneration Committee**”) and (the “**Nomination Committee**”) due to her intention to concentrate on her other business commitments with effect from 20 January 2026.

Ms. Meng has confirmed that she has no disagreement with the Board, and that she was not aware of other matters that need to be brought to the attention of the shareholders of the Company (the “**Shareholders**”) in connection with her decision to resign.

The Board wishes to express its sincere gratitude to Ms. Meng for her valuable contribution to the Company during her tenure of services.

CHANGES IN COMPOSITION OF BOARD COMMITTEES

Following the resignation of the director, Ms. Meng ceased to be an executive Director, and a member of each of the Remuneration Committee and the Nomination Committee of the Company with effect from 20 January 2026.

The Board also announces that with effect from 20 January 2026, Mr. Li Runping, an executive Director, has been appointed as a member of each of the Remuneration Committee and Nomination Committee.

DIVERSITY OF BOARD MEMBERS UNDER RULE 13.92 OF THE LISTING RULES

Pursuant to Rule 13.92 of the Listing Rules, the Stock Exchange will not consider diversity to be achieved for a single gender board. Following the resignation of Ms. Meng as executive Directors with effect from 20 January 2026, the Company has a single gender board which does not meet the requirement under Rule 13.92 of the Listing Rules.

The Board will use its best endeavour to identify a suitable female candidate that meet relevant requirements. In making the appointment of a Director, a number of factors including but not limited to gender, age, cultural and educational background, ethnicity, professional experience, skills and knowledge will be taken into account with an aim to make the Board more diverse, and the decision will be made based on merits in accordance with the nomination policy of the Company.

It is expected that the Board will appoint a suitable female candidate as Director within three months from the date of the resignation in order to ensure compliance by the Company with the requirement under Rule 13.92 of the Listing Rules. Further announcement will be made by the Company as and when appropriate.

CLARIFICATION ANNOUNCEMENT

Reference is made to the announcement of change of principal office in Hong Kong of the Company dated 29 August 2025 (the “**Announcement**”). Unless otherwise defined, capitalised terms used in this announcement shall have the same meanings as those defined in the Announcement. The Company would like to clarify a typo error of the address of the principal office of Company (the “**Address**”). The approximate Address should be “12B, 16/F., BEA Tower of Millennium City 5, 418 Kwun Tong Road, Kwun Tong, Hong Kong” which the floor of the Address was omitted. Save for the above, all other information stated in the Announcements remains unchanged.

CONTINUED SUSPENSION OF TRADING

At the request of the Company, trading in the shares of the Company on the Stock Exchange has been suspended since 9:54 a.m. on 21 February 2025 and will remain suspended until further notice.

Shareholders and potential investors of the Company should exercise caution when dealing in the securities of the Company.

By Order of the Board
Aidigong Maternal & Child Health Limited
Huang Wenhua
Chairman and Chief Executive Officer

Hong Kong, 20 January 2026

As at the date of this announcement, the Board comprises Mr. Huang Wenhua and Mr. Li Runping as executive Directors; and Mr. Wang Bin and Mr. Ma Siu Kit as independent non-executive Directors.